ArticleClinical kidney journal2026

A decade of complement inhibition in post-transplant atypical HUS: outcomes with eculizumab and ravulizumab.

Naga Sumanth Reddy Gopireddy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.